Capricor Therapeutics: Heavily Derisked After BLA Submission And OLE Data

Group 1 - Capricor Therapeutics submitted its Biologics License Application (BLA) for deramiocel, targeting patients with Duchenne muscular dystrophy (DMD) cardiomyopathy [1] - The company highlighted that deramiocel is slowing the progression of cardiac dysfunction in DMD patients [1]